학술논문
Selective MEK Inhibition with AZD-6244 (selumetinib) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A University of Chicago Phase II Consortium Trial
Document Type
Abstract
Author
Source
In Blood 3 December 2015 126(23):3990-3990
Subject
Language
ISSN
0006-4971